CVS Health Co. (NYSE:CVS) Expected to Announce Quarterly Sales of $76.46 Billion

Analysts forecast that CVS Health Co. (NYSE:CVS – Get Rating) will report sales of $76.46 billion for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for CVS Health’s earnings. The lowest sales estimate is $76.13 billion and the highest is $76.70 billion. CVS Health reported sales of $72.62 billion in the same quarter last year, which indicates a positive year over year growth rate of 5.3%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that CVS Health will report full-year sales of $307.26 billion for the current financial year, with estimates ranging from $306.38 billion to $308.00 billion. For the next fiscal year, analysts expect that the company will report sales of $321.25 billion, with estimates ranging from $318.72 billion to $323.94 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for CVS Health.

CVS Health (NYSE:CVS – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The pharmacy operator reported $2.22 EPS for the quarter, beating the consensus estimate of $2.14 by $0.08. CVS Health had a return on equity of 15.15% and a net margin of 2.71%. The company had revenue of $76.83 billion for the quarter, compared to analyst estimates of $75.30 billion. During the same period last year, the company earned $2.04 earnings per share. CVS Health’s quarterly revenue was up 11.2% compared to the same quarter last year.

Several analysts have commented on the company. Sanford C. Bernstein raised their price objective on CVS Health from $111.00 to $116.00 in a report on Tuesday, January 11th. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research note on Monday, January 10th. BMO Capital Markets lifted their price target on CVS Health from $108.00 to $120.00 in a research note on Thursday, February 10th. Robert W. Baird lifted their price objective on CVS Health from $107.00 to $110.00 in a research report on Wednesday, January 12th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on CVS Health from $110.00 to $113.00 in a research report on Thursday. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has an average rating of “Buy” and a consensus price target of $114.90.

Shares of CVS opened at $97.73 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. CVS Health has a 12 month low of $79.33 and a 12 month high of $111.25. The stock’s 50 day moving average is $103.63 and its two-hundred day moving average is $100.51. The firm has a market cap of $128.34 billion, a P/E ratio of 16.40, a PEG ratio of 1.54 and a beta of 0.78.

The business also recently declared a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 22nd were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Thursday, April 21st. This represents a $2.20 annualized dividend and a yield of 2.25%. CVS Health’s dividend payout ratio (DPR) is 36.91%.

In other CVS Health news, Director Edward J. Ludwig acquired 1,000 shares of the company’s stock in a transaction dated Thursday, February 10th. The shares were acquired at an average price of $105.90 per share, for a total transaction of $105,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel P. Finke sold 55,359 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $100.13, for a total value of $5,543,096.67. Following the completion of the transaction, the executive vice president now owns 3,098 shares in the company, valued at approximately $310,202.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,283 shares of company stock worth $8,376,142. 0.69% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. West Bancorporation Inc. purchased a new position in shares of CVS Health in the 4th quarter valued at about $25,000. Macroview Investment Management LLC increased its holdings in shares of CVS Health by 128.3% in the 1st quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock valued at $25,000 after acquiring an additional 136 shares during the last quarter. Bell Investment Advisors Inc purchased a new position in CVS Health during the 3rd quarter worth approximately $26,000. Claremont Financial Group Inc. purchased a new position in CVS Health during the 4th quarter worth approximately $26,000. Finally, Stuart Chaussee & Associates Inc. grew its stake in CVS Health by 123.0% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Recommended Stories